Cardiovascular Pathology

2004

DOI: 10.1016/j.carpath.2004.03.039

|View full text |Cite

|

Sign up to set email alerts

|

Altered Vascular Remodeling in Osteopontin Deficient Atherosclerotic Mice

Ahnders Franzén²,

Christel Wängnerud³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion2

Results1

Bioinformatics1

The Génic Study1

Citation Types

Supporting

2

Mentioning

23

Contrasting

0

Year Published

2005

2005

2011

2011

Publication Types

Select...

Article7

Relationship

Self Cite0

Independent7

Authors

Journals

Cited by 20 publications

(25 citation statements)

References 0 publications

Supporting

2

Mentioning

23

Contrasting

0

Order By: Relevance

“…Next, we selected proteins that have been identified earlier in experimental set-ups with any cardiovascular phenotype but not necessarily with atherosclerosis (OPN [17][18][19][20] ; MIF 21 ). Then, we searched whether a detection tool was commercially available (eg, a commercial enzyme-linked immunosorbent assay or Luminex).…”

Section: Resultsmentioning

confidence: 99%

“…Within this network, OPN was selected based on its previously described relation with atherosclerosis [17][18][19][20] and the availability of an assay, as well as macrophage migration inhibitory factor (MIF). 21,22 Osteopontin Enzyme-Linked Immunosorbent Assay A commercial Osteopontin enzyme-linked immunosorbent assay (DOST00; R&D Systems) was used according to the described procedures.…”

Section: Bioinformaticsmentioning

confidence: 99%

See 1 more Smart Citation

Local Atherosclerotic Plaques Are a Source of Prognostic Biomarkers for Adverse Cardiovascular Events

¹

,

²

,

³

et al. 2010

View full text Add to dashboard Cite

Objective-Atherosclerotic cardiovascular disease is a major burden to health care. Because atherosclerosis is considered a systemic disease, we hypothesized that one single atherosclerotic plaque contains ample molecular information that predicts future cardiovascular events in all vascular territories. Methods and Results-AtheroExpress is a biobank collecting atherosclerotic lesions during surgery, with a 3-year follow-up. The composite primary outcome encompasses all cardiovascular events and interventions, eg, cardiovascular death, myocardial infarction, stroke, and endovascular interventions. A proteomics search identified osteopontin as a potential plaque biomarker. Patients undergoing carotid surgery (nϭ574) served as the cohort in which plaque osteopontin levels were examined in relation to their outcome during follow-up and was validated in a cohort of patients undergoing femoral endarterectomy (nϭ151). Comparing the highest quartile of carotid plaque osteopontin levels with quartile 1 showed a hazard ratio for the primary outcome of 3.8 (95% confidence interval, 2.6 -5.9). The outcome did not change after adjustment for plaque characteristics and traditional risk factors (hazard ratio, 3.5; 95% confidence interval, 2.0 -5.9). The femoral validation cohort showed a hazard ratio of 3.8 (95% confidence interval 2.0 to 7.4) comparing osteopontin levels in quartile 4 with quartile 1. Key Words: arterectomy Ⅲ atherosclerosis Ⅲ biomarker Ⅲ plaque A dvanced atherosclerotic cardiovascular disease continues to be a major burden to health care expenditures and requires exhaustive forms of medical treatment. A pressing need exists for prognostic biomarkers to identify high-risk patients for aggressive treatment. Conclusion-PlaqueProteins in the plasma are easily accessible and can serve as a surrogate measure of atherosclerotic disease progression, but existing circulating biomarkers do not provide an accurate value of predictive patient risk. 1,2 The main focus toward identifying patients with rapidly progressive advanced atherosclerotic disease is based on the known characteristics of the vulnerable or recently ruptured plaque with typically a large lipid core, thin fibrous cap, a high number of inflammatory cells, and thrombus. [3][4][5][6] The pathological definition of the vulnerable plaque is founded on cross-sectional studies. Subsequently, molecular and cellular features associated with the vulnerable plaque are considered potential diagnostic imaging markers for plaque rupture and plaque thrombosis. However, longitudinal studies supporting the predictive power of these pathological markers have not been executed, and information about the natural history of atherosclerotic disease is therefore incomplete. The systemic nature of atherosclerotic disease, however, is well-established 7-9 through histopathologic observations demonstrating that inflammation, 10 morphology, 11 and lipid content 12 correlate between different arterial segments within 1 individual. This gave rise to the hypothesis that local plaqu...

“…Next, we selected proteins that have been identified earlier in experimental set-ups with any cardiovascular phenotype but not necessarily with atherosclerosis (OPN [17][18][19][20] ; MIF 21 ). Then, we searched whether a detection tool was commercially available (eg, a commercial enzyme-linked immunosorbent assay or Luminex).…”

Section: Resultsmentioning

confidence: 99%

“…Within this network, OPN was selected based on its previously described relation with atherosclerosis [17][18][19][20] and the availability of an assay, as well as macrophage migration inhibitory factor (MIF). 21,22 Osteopontin Enzyme-Linked Immunosorbent Assay A commercial Osteopontin enzyme-linked immunosorbent assay (DOST00; R&D Systems) was used according to the described procedures.…”

Section: Bioinformaticsmentioning

confidence: 99%

Local Atherosclerotic Plaques Are a Source of Prognostic Biomarkers for Adverse Cardiovascular Events

¹

,

²

,

³

et al. 2010

View full text Add to dashboard Cite

Objective-Atherosclerotic cardiovascular disease is a major burden to health care. Because atherosclerosis is considered a systemic disease, we hypothesized that one single atherosclerotic plaque contains ample molecular information that predicts future cardiovascular events in all vascular territories. Methods and Results-AtheroExpress is a biobank collecting atherosclerotic lesions during surgery, with a 3-year follow-up. The composite primary outcome encompasses all cardiovascular events and interventions, eg, cardiovascular death, myocardial infarction, stroke, and endovascular interventions. A proteomics search identified osteopontin as a potential plaque biomarker. Patients undergoing carotid surgery (nϭ574) served as the cohort in which plaque osteopontin levels were examined in relation to their outcome during follow-up and was validated in a cohort of patients undergoing femoral endarterectomy (nϭ151). Comparing the highest quartile of carotid plaque osteopontin levels with quartile 1 showed a hazard ratio for the primary outcome of 3.8 (95% confidence interval, 2.6 -5.9). The outcome did not change after adjustment for plaque characteristics and traditional risk factors (hazard ratio, 3.5; 95% confidence interval, 2.0 -5.9). The femoral validation cohort showed a hazard ratio of 3.8 (95% confidence interval 2.0 to 7.4) comparing osteopontin levels in quartile 4 with quartile 1. Key Words: arterectomy Ⅲ atherosclerosis Ⅲ biomarker Ⅲ plaque A dvanced atherosclerotic cardiovascular disease continues to be a major burden to health care expenditures and requires exhaustive forms of medical treatment. A pressing need exists for prognostic biomarkers to identify high-risk patients for aggressive treatment. Conclusion-PlaqueProteins in the plasma are easily accessible and can serve as a surrogate measure of atherosclerotic disease progression, but existing circulating biomarkers do not provide an accurate value of predictive patient risk. 1,2 The main focus toward identifying patients with rapidly progressive advanced atherosclerotic disease is based on the known characteristics of the vulnerable or recently ruptured plaque with typically a large lipid core, thin fibrous cap, a high number of inflammatory cells, and thrombus. [3][4][5][6] The pathological definition of the vulnerable plaque is founded on cross-sectional studies. Subsequently, molecular and cellular features associated with the vulnerable plaque are considered potential diagnostic imaging markers for plaque rupture and plaque thrombosis. However, longitudinal studies supporting the predictive power of these pathological markers have not been executed, and information about the natural history of atherosclerotic disease is therefore incomplete. The systemic nature of atherosclerotic disease, however, is well-established 7-9 through histopathologic observations demonstrating that inflammation, 10 morphology, 11 and lipid content 12 correlate between different arterial segments within 1 individual. This gave rise to the hypothesis that local plaqu...

“…With respect to the link between OPN and plasma apoB levels, Strom et al [15] reported significantly decreased total plasma cholesterol levels in apoE/LDL receptor/OPN triple knockout compared to apoE/LDL receptor-deficient mice. Other cytokines such as IL-1 and TNF-␣ have been shown to decrease apoB secretion in human fetal hepatocytes by decreasing MTP large subunit mRNA and protein expression in HepG2 cells.…”

Section: Discussionmentioning

confidence: 99%

“…Using a backwards selection procedure, OPN D147D was removed with a P-value of 0. 15 Table 3 Distribution of OPN D147D T/C genotypes in cases with BI and controls (GÉNIC Study). a Logistic regression was used for categorical variables, and analyses of covariance for continuous variables, both adjusted on age, gender and cases-control status.…”

Section: The Génic Studymentioning

confidence: 99%

Osteopontin gene variation and cardio/cerebrovascular disease phenotypes

Schmidt-Petersen

¹

,

³

et al. 2009

Atherosclerosis

View full text Add to dashboard Cite

a b s t r a c tWe aimed at associating common osteopontin (OPN) gene variants with cardiovascular disease phenotypes.We scanned the OPN gene in 190 chromosomes from myocardial infarction (MI) patients and identified five variants in the promoter, three synonymous and one non-synonymous variant. All variants were investigated in case-control studies for MI (ECTIM: 990 cases, 900 controls) and brain infarction (BI) (GÉNIC: 466 cases, 444 controls). Promoter variants were functionally analyzed by bandshift assays, the coding D147D [T/C] by Western blot. Allele D147D C was independently and significantly associated with lower apoB levels (P = 0.044 [ECTIM] P = 0.03 [GENIC]), its allele frequency was significantly lower in patients with BI compared to controls (OR [95% CI] 0.39 [0.20-0.74], P = 0.004), and C allele carriers had a significantly lower frequency of presence of carotid plaques (P = 0.02). Bandshifts with HepG2 and Ea.hy926 nuclear proteins did not reveal any functionality of promoter variants, whereas the OPN-441C-containing construct resulted in reduced OPN protein expression in Western blots, complying with its potential protective effect on the phenotypes studied.We here provide evidence that a portion of the OPN locus is likely to associate with cardiovascular disease-related phenotypes. However, further experiments are warranted to clarify the functional role of OPN variants.

“…Immunohistochemistry demonstrated a strong staining of OPN in the lesions of ApoE/LDL receptor-deficient (AL) mice; whereas it was absent in ApoE/LDL receptor/OPN triple knockout (ALO) mice as well as in the media of ApoE/ LDL receptor-deficient (AL) mice [28]. The medial layers of the carotid arteries of streptozotocin-induced diabetic rats and the forearm arteries of diabetic patients stained positively for OPN antibodies, whereas the staining from arteries of control rats and nondiabetic patients was negative [29].…”

Section: Discussionmentioning

confidence: 99%

Osteopontin expression and its possible functions in the aortic disorders and coronary artery disease

Yuan¹,

Wang²,

et al. 2011

Rev Bras Cir Cardiovasc

View full text Add to dashboard Cite

Background: Osteopontin (OPN) has been verified to be closely associated with oncogenesis and remodeling processes. But this cytokine was rarely assessed in the presence of aortopathies, especially acute aortic dissection. The aim of the present study was to evaluate the expressions of OPN by way of molecular biological approaches so as to offer a better understanding of the possible mechanisms of the aortopathies.Methods: Consecutive patients with type A acute aortic dissection (20 patients), aortic aneurysm (nine patients) or coronary artery disease (21 patients) referred to this hospital for surgical operations were enrolled into this study. Blood samples of the surgical patients after systematic heparinization, and control fast morning blood samples drawn from 21 young healthy volunteers who had no evidence of any healthy problems were investigated for enzyme linked immunosorbent assay (ELISA). The surgical specimens of the aortic tissues collected from the surgical patients during the operations were obtained for quantitative realtime reverse transcription polymerase chain reaction (RT-PCR) for OPN mRNA, western blot assay for OPN protein, and for immunohistochemical staining of OPN. Ascending aortic tissues from the autopsies of the healthy individuals dying of accident were obtained as controls of immunohistochemistry.Results: By quantitative RT-PCR, the expressions of OPN mRNA were all upregulated in all three surgical groups. The quantitative results did not reveal any intergroup

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Product

Browser Extension Assistant by scite Citation Statement Search Reference Check Visualizations Dashboards Explore Journals Explore Organizations Explore Funders Embedding Badge Embedding Citation Search Pricing

Resources

Blog Help & FAQ Accessibility Statement API Terms For Universities & Governments For Researchers For Publishers For Corporate, Pharma & Enterprise Author Marketing Become an Affiliate Get an organization trial or quote scite Data & Services

About

News & Press Careers Read our Paper Coverage

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Copyright © 2024 scite LLC. All rights reserved.

Made with 💙 for researchers

Part of the Research Solutions Family.